Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage

BMC Nephrology

Volumn 20, Issue 1, 2019, Pages

  Reyes Pardo, Humberto ^a   Bautista, Rocío ^b   Vargas Robles, Hilda ^a   Rios, Amelia ^a   Sánchez, Daniel ^a   Escalante, Bruno ^a,c  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c Monterrey   (Mexico)

Author keywords

Angiotensin II; Kidney damage; ROS; SGLT2

Indexed keywords

ANGIOTENSIN II; EMPAGLIFLOZIN; INULIN; LOSARTAN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZHYDRYL DERIVATIVE; GLUCOSE; GLUCOSIDE; SLC5A2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRUSH BORDER MEMBRANE VESICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GLUCOSE TRANSPORT; IMMUNOBLOTTING; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RAT MODEL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; WISTAR RAT; ACUTE KIDNEY FAILURE; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; GENETICS; HYPERTENSION; METABOLISM; MICROVILLUS; PHARMACOLOGY; PROTEINURIA;

ACUTE KIDNEY INJURY; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; HYPERTENSION; LOSARTAN; MALE; MICROVILLI; PROTEINURIA; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85070224442     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-019-1490-z     Document Type: Article

References (30)

1. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. J Hypertens. 2001;19(6):1053-60.
2. Wang X, Armando I, Upadhyay K, Pascua A, Jose PA. The regulation of proximal tubular salt transport in hypertension: an update. Curr Opin Nephrol Hypertens. 2009;18(5):412-20.
3. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397-404.
4. +-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10-8.
5. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14:782-90.
6. Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010;10(4):193-9.
7. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-24.
8. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-33.
9. +-glucose cotransporter in hypertension. Am J Physiol Renal Physiol. 2004;286:F127-33.
10. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-97.
11. Cozzolino M, Gentile G, Mazzaferro S, Brancaccio D, Ruggenenti P, Remuzzi G. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. Am J Kidney Dis. 2013;62(5):984-92.
12. Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, Escalante B. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxidative Med Cell Longev. 2012;2012(542042):1-7.
13. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR Ob/Ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307(3):F317-25.
14. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-26.
15. Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuria renal disease. Curr Opin Pharmacol. 2017;33:34-40.
16. Hernández J, Astudillo H, Escalante B. Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure. Am J Physiol Renal Physiol. 2002;282(4):F592-8.
17. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension. 1999;34(4 Pt 2):848-53.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-54.
19. Arellano-Mendoza MG, Castillo-Henkel C, Medina-Santillan R, Jarillo-Luna RA, Vargas-Robles H, Romo E, Rios A, Escalante B. Kidney damage after renal ablation is worsened in endothelial nitric oxide synthase -/- mice and improved by combined administration of L-arginine and antioxidants. Nephrology. 2008;13(3):218-27.
20. Osorio H, Bautista R, Rios A, Franco M, Arellano A, Vargas-Robles H, Romo E, Escalante B. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol. 2010;23(5):541-6.
21. Osorio H, Bautista R, Rios A, Franco M, Santamaría J, Escalante B. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract. 2009;86:46-9.
22. Canale D, Rodrigues MV, Ferreira DN, Machado FG, Veras MM, Malheiros DM, Krieger JE, Fujihara CK, Venturini G, Zatz R. Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms. Hypertens Res. 2011;34(6):693-700.
23. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol. 1999;10(8):1778-85.
24. + transporter and channel abundances in angiotensin II type 1a receptor knockout mice. Hypertension. 2002;39(2 Pt 2):470-3.
25. Jensen AM, Li C, Praetorius HA, Nørregaard R, Frische S, Knepper MA, Nielsen S, Frøkiaer J. Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. Am J Physiol Renal Physiol. 2006;291(5):F1021-32.
26. Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, Marmot M, for the Intersalt Cooperative Research Group. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ. 1996;312(7041):1249-53.
27. Karet FE, Lifton RP. Mutations contributing to human blood pressure variation. Recent Prog Horm Res. 1997;52:263-76.
28. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kusiel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52(2):256-63.
29. Agarwal R, Campbell RC, Warnock DC. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol. 2004;24(2):101-14.
30. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1009-22.